表紙
市場調查報告書

熱門市場分析:乾燥症(修格蘭氏症候群)

Market Spotlight: Sjogren's Syndrome

出版商 Datamonitor Healthcare 商品編碼 594582
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
熱門市場分析:乾燥症(修格蘭氏症候群) Market Spotlight: Sjogren's Syndrome
出版日期: 2019年11月21日內容資訊: 英文 35 Pages
簡介

本報告提供乾燥症的治療藥市場相關分析,提供疾病概要和患者數的轉變·預測,目前的主要治療方法及臨床實驗·認證情形,乾燥症治療藥市場趨勢預測 (今後10年份),資本交易的動向,現在開發中臨床實驗的進展等調查。

分析的要點

疾病的背景情況

治療方法

  • 乾眼症
  • 乾唇
  • 其他腺體相關的疾病表現
  • 腺體以外的疾病表現

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

今後的市場主要動向

授權合約·資產收購交易 (1件)

母體專利

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各期

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0182069

This Market Spotlight report covers the Sjogren's syndrome market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were approximately 2.3 million prevalent cases of primary Sjogren's syndrome worldwide, and forecasts that number to increase to 2.5 million prevalent cases by

2027. Primary Sjogren's syndrome has a female predominance. Globally, Datamonitor Healthcare estimates that in 2018, 90.4% of cases aged 15 years and over were female.

Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjogren's syndrome.

The majority of industry-sponsored drugs in active clinical development for Sjogren's syndrome are in Phase II, with only one drug in Phase III.

Therapies in development for Sjogren's syndrome focus on a wide variety of targets. The pipeline drugs for Sjogren's syndrome are administered via the oral, intravenous, and subcutaneous routes.

The only high-impact upcoming event in the Sjogren's syndrome space is topline Phase II trial results for Benlysta SC. The overall likelihood of approval of a Phase I arthritis asset is 9.6%, and the average probability a drug advances from Phase III is 78.3%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.

There have been only four licensing and asset acquisition deals involving Sjogren's syndrome drugs during 2014-19. The exclusive licensing and collaboration agreement between Eli Lilly and Hanmi for $690m, regarding the development and commercialization of Hanmi's oral BTK inhibitor HM71224 for the treatment of autoimmune and other diseases, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjogren's syndrome have been in the early and mid-phases of development, with 72% of trials in Phase I-II, and only 28% in Phase III-IV.

The US has a substantial lead in the number of Sjogren's syndrome clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the Sjogren's syndrome space is dominated by completed trials. Roche has the highest number of completed clinical trials for Sjogren's syndrome, with eight trials.

Novartis leads the industry sponsors with the highest overall number of clinical trials for Sjogren's syndrome, followed by BristolMyers Squibb.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

8 TREATMENT

8 Dry eyes

8 Dry mouth

8 Other glandular manifestations

9 Extraglandular manifestations

10 EPIDEMIOLOGY

15 MARKETED DRUGS

17 PIPELINE DRUGS

22 RECENT EVENTS AND ANALYST OPINION

22 Mutliple Drugs for Sjogren's Syndrome (October 24, 2019)

22 RSLV-132 for Sjogren's Syndrome (June 13, 2019)

25 KEY UPCOMING EVENTS

26 PROBABILITY OF SUCCESS

27 LICENSING AND ASSET ACQUISITION DEALS

27 Advanz Obtains Two Commercial Products From Eisai

28 PARENT PATENTS

29 CLINICAL TRIAL LANDSCAPE

30 Sponsors by status

31 Sponsors by phase

33 BIBLIOGRAPHY

33 Prescription information

34 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of primary Sjogren's syndrome, 2018-27
  • 17 Figure 2: Overview of pipeline drugs for Sjogren's syndrome in the US
  • 17 Figure 3: Pipeline drugs for Sjogren's syndrome, by company
  • 18 Figure 4: Pipeline drugs for Sjogren's syndrome, by drug type
  • 18 Figure 5: Pipeline drugs for Sjogren's syndrome, by classification
  • 24 Figure 6: RSLV-132 for Sjogren's Syndrome (June 13, 2019): Phase II - Study 132-04
  • 25 Figure 7: Key upcoming events in Sjogren's syndrome
  • 26 Figure 8: Probability of success in the Sjogren's syndrome pipeline
  • 27 Figure 9: Licensing and asset acquisition deals in Sjogren's syndrome, 2014-19
  • 28 Figure 10: Parent patents in Sjogren's syndrome
  • 29 Figure 11: Clinical trials in Sjogren's syndrome
  • 29 Figure 12: Top 10 drugs for clinical trials in Sjogren's syndrome
  • 30 Figure 13: Top 10 companies for clinical trials in Sjogren's syndrome
  • 30 Figure 14: Trial locations in Sjogren's syndrome
  • 31 Figure 15: Sjogren's syndrome trials status
  • 32 Figure 16: Sjogren's syndrome trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of primary Sjogren's syndrome, 2018-27
  • 13 Table 2: Prevalent cases of primary Sjogren's syndrome, by gender, 2018
  • 14 Table 3: Prevalence of primary Sjogren's syndrome, by gender, 2018
  • 16 Table 4: Marketed drugs for Sjogren's syndrome
  • 19 Table 5: Pipeline drugs for Sjogren's syndrome in the US
  • 22 Table 6: Mutliple Drugs for Sjogren's Syndrome (October 24, 2019)
  • 23 Table 7: RSLV-132 for Sjogren's Syndrome (June 13, 2019)